Sandoz closes Oriel Therapeutics deal

PRINCETON, N.J. Sandoz has acquired privately owned U.S. drug maker Oriel Therapeutics, the generics arm of Novartis said Thursday. Financial terms of the deal were not disclosed.

Sandoz said its purchase of Oriel would give it access to such drug-delivery technologies as FreePath and the Solis disposable dry-powder inhaler, itself based on FreePath technology.

“The closing of the Oriel Therapeutics acquisition is an important milestone in our aspiration to a global leadership position in differentiated, high-value respiratory products,” said Don DeGolyer, president of Sandoz’s U.S. division. “We welcome the Oriel employees into our organization and look forward to our ongoing work together to strengthen Sandoz’s position in the respiratory market.”